Weinberg E O, Lee M A, Weigner M, Lindpaintner K, Bishop S P, Benedict C R, Ho K K, Douglas P S, Chafizadeh E, Lorell B H
Charles A. Dana Research Institute, Boston, Mass, USA.
Circulation. 1997 Mar 18;95(6):1592-600. doi: 10.1161/01.cir.95.6.1592.
We tested the hypothesis that long-term administration of the specific angiotensin II subtype 1 (AT1)-receptor blocker BMS-186295 will regress hypertrophy and modify left ventricular angiotensin converting enzyme (ACE) expression in rats with ascending aortic stenosis.
Six weeks after surgery, rats with ascending aortic stenosis were randomized to receive either the AT1-receptor blocker BMS-186295 50 mg.kg-1.d-1 (n = 49), amlodipine 2.5 mg.kg-1.d-1 (n = 48) as a positive control for systemic vasodilation, or no drug (n = 48) and compared with sham-operated rats (n = 39). Drug treatment was continued for 15 weeks. Left ventricular ACE mRNA levels were measured by ribonuclease protection assay. The left ventricular/body weight ratio was increased 43% in hearts from rats with untreated left ventricular hypertrophy (LVH) versus control hearts (P < .05). However, there was no difference in either the left ventricular/body weight ratio (2.78 +/- 0.08 versus 2.81 +/- 0.20 mg/g; P = NS) or myocyte cross-sectional area in the AT1-blocker-treated versus untreated LVH hearts. Amlodipine also showed no effect on regression of hypertrophy. In vivo left ventricular systolic pressure was significantly higher in untreated LVH versus sham-operated rats (193 +/- 8 versus 118 +/- 4 mm Hg; P < .05), and there was a similar severe elevation of left ventricular systolic pressure in the AT1-blocker- and amlodipine-treated LVH groups (189 +/- 9 and 188 +/- 16 mm Hg; P = NS versus untreated LVH). In vivo left ventricular end-diastolic pressure was higher in the untreated LVH than in the sham-operated rats (14.8 +/- 2.3 versus 7.0 +/- 0.5 mm Hg; P < .05). Left ventricular end-diastolic pressure was lower in the AT1-blocker-treated (11.0 +/- 1.7 mm Hg) and amlodipine-treated rats (11.5 +/- 1.8 mm Hg) and was similar to left ventricular end-diastolic pressure in the sham-operated rats (P = NS). Left ventricular ACE mRNA levels were elevated in untreated LVH rats but were normalized in both the AT1-blocker-treated rats and amlodipine-treated rats.
Long-term AT1-receptor blockade did not regress LVH in rats with persistent systolic pressure overload due to ascending aortic stenosis. However, both AT1-receptor blockade and amlodipine improved in vivo left ventricular end-diastolic pressure in association with the normalization of left ventricular ACE mRNA levels.
我们检验了以下假设,即长期给予特异性血管紧张素II 1型(AT1)受体阻滞剂BMS-186295可使升主动脉狭窄大鼠的心肌肥厚消退,并改变左心室血管紧张素转换酶(ACE)的表达。
术后6周,将升主动脉狭窄大鼠随机分为三组,分别接受AT1受体阻滞剂BMS-186295 50mg·kg-1·d-1(n = 49)、氨氯地平2.5mg·kg-1·d-1(n = 48,作为全身血管舒张的阳性对照)或不接受药物治疗(n = 48),并与假手术大鼠(n = 39)进行比较。药物治疗持续15周。通过核糖核酸酶保护试验测量左心室ACE mRNA水平。与对照心脏相比,未经治疗的左心室肥厚(LVH)大鼠心脏的左心室/体重比增加了43%(P < 0.05)。然而,AT1受体阻滞剂治疗组与未治疗的LVH心脏组相比,左心室/体重比(2.78±0.08对2.81±0.20mg/g;P = 无显著性差异)或心肌细胞横截面积均无差异。氨氯地平对心肌肥厚的消退也无作用。未经治疗的LVH大鼠的体内左心室收缩压显著高于假手术大鼠(193±8对118±4mmHg;P < 0.05),AT1受体阻滞剂治疗组和氨氯地平治疗组的LVH大鼠左心室收缩压也有类似的严重升高(189±9和188±16mmHg;与未治疗的LVH相比P = 无显著性差异)。未经治疗的LVH大鼠的体内左心室舒张末期压力高于假手术大鼠(14.8±2.3对7.0±0.5mmHg;P < 0.05)。AT1受体阻滞剂治疗组(11.0±1.7mmHg)和氨氯地平治疗组大鼠的左心室舒张末期压力较低,与假手术大鼠的左心室舒张末期压力相似(P = 无显著性差异)。未经治疗的LVH大鼠左心室ACE mRNA水平升高,但在AT1受体阻滞剂治疗组大鼠和氨氯地平治疗组大鼠中均恢复正常。
长期AT1受体阻断不能使因升主动脉狭窄导致持续性收缩压过载的大鼠的LVH消退。然而,AT1受体阻断和氨氯地平均可改善体内左心室舒张末期压力,并使左心室ACE mRNA水平恢复正常。